Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cerilliant
Accenture
Teva
Deloitte
Chubb
Fish and Richardson
UBS
Harvard Business School

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NAPROXEN SODIUM

« Back to Dashboard

Clinical Trials for Naproxen Sodium

Trial ID Title Status Sponsor Phase Summary
NCT00092729 An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of this study is to evaluate the pain relieving effect and safety of an investigational drug in women with moderate to severe primary dysmenorrhea (painful menstruation).
NCT00114049 Dental Pain (Following Third Molar Tooth Extraction) Study Completed GlaxoSmithKline Phase 3 The purpose of this study is to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of dental pain following third molar tooth extraction.
NCT00240617 Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks Completed GlaxoSmithKline Phase 3 The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
NCT00240630 Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks Completed GlaxoSmithKline Phase 3 The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
NCT00261586 A Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach Completed Johnson & Johnson Consumer and Personal Products Worldwide Phase 4 The purpose of this study is to compare several analgesics given in approved daily doses in combination with a daily cardioprotective dose of aspirin (81 mg), to study their bleeding properties and their effects on the stomach in healthy volunteers.
NCT00329355 Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA) Completed GlaxoSmithKline Phase 3 This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00329459 Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea Completed GlaxoSmithKline Phase 3 This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Naproxen Sodium

Condition Name

Condition Name for Naproxen Sodium
Intervention Trials
Migraine Disorders 16
Healthy 10
Pain 8
Migraine 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Naproxen Sodium
Intervention Trials
Migraine Disorders 25
Toothache 6
Pain, Postoperative 5
Dysmenorrhea 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Naproxen Sodium

Trials by Country

Trials by Country for Naproxen Sodium
Location Trials
United States 358
India 4
Canada 3
Brazil 2
Turkey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Naproxen Sodium
Location Trials
Texas 26
Utah 19
California 16
Florida 15
Ohio 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Naproxen Sodium

Clinical Trial Phase

Clinical Trial Phase for Naproxen Sodium
Clinical Trial Phase Trials
Phase 4 16
Phase 3 24
Phase 2/Phase 3 2
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Naproxen Sodium
Clinical Trial Phase Trials
Completed 63
Recruiting 8
Unknown status 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Naproxen Sodium

Sponsor Name

Sponsor Name for Naproxen Sodium
Sponsor Trials
GlaxoSmithKline 21
Bayer 20
Dr. Reddy's Laboratories Limited 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Naproxen Sodium
Sponsor Trials
Industry 63
Other 32
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Fuji
Accenture
Farmers Insurance
US Department of Justice
Fish and Richardson
Covington
McKinsey
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.